Production of human recombinant phenylalanine hydroxylase in Lactobacillus plantarum for gastrointestinal delivery

European Journal of Pharmaceutical Sciences

Volumn 109, Issue , 2017, Pages 48-55

  Ramírez, Aura María ^a   Rodriguez López, Alexander ^a   Ardila, Andrea ^b   Beltran, Laura ^a   Patarroyo, Camilo Andres ^a   Melendez, Adelina Del Pilar ^c   Sánchez, Oscar Fernando ^d   Alméciga Díaz, Carlos Javier ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

^c UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^d PURDUE UNIVERSITY   (United States)

Author keywords

Caco 2 cells; Lactobacilli; Phenylalanine hydroxylase; Phenylketonuria

Indexed keywords

BACTERIAL VECTOR; DIPEPTIDYL PEPTIDASE IV; DRUG VEHICLE; GLYCINE; LACTASE; MICROSOMAL AMINOPEPTIDASE; OLIGO 1,6 GLUCOSIDASE; PHENYLALANINE 4 MONOOXYGENASE; PROBIOTIC AGENT; RECOMBINANT PHENYLALANINE HYDROXYLASE; RECOMBINANT PROTEIN; SIGNAL PEPTIDE; SUCRASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CACO-2 CELL LINE; CLINICAL ASSESSMENT; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPRESSION VECTOR; GASTROINTESTINAL TRACT; HUMAN; LACTOBACILLUS PLANTARUM; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHENYLKETONURIA; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; DRUG DELIVERY SYSTEM; GENETICS; METABOLISM;

CACO-2 CELLS; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL TRACT; HUMANS; LACTOBACILLUS PLANTARUM; PHENYLALANINE HYDROXYLASE; PROBIOTICS; RECOMBINANT PROTEINS;

EID: 85026675880     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2017.07.033     Document Type: Article

References (56)

1. Agarwal, P., Khatri, P., Billack, B., Low, W.K., Shao, J., Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis. Pharm. Res. 31 (2014), 3404–3414.
2. Alegre, M.T., Rodríguez, M.C., Mesas, J.M., Transformation of Lactobacillus plantarum by electroporation with in vitro modified plasmid DNA. FEMS Microbiol. Lett. 241 (2004), 73–77.
3. Bartholome, K., Lutz, P., Bickel, H., Determination of phenylalanine hydroxylase activity in patients with phenylketonuria and hyperphenylalaninemia. Pediatr. Res. 9 (1975), 899–903.
4. Berlec, A., Ravnikar, M., Štrukelj, B., Lactic acid bacteria as oral delivery systems for biomolecules. Pharmazie 67 (2012), 891–898.
5. Bermudez-Brito, M., Munoz-Quezada, S., Gomez-Llorente, C., Matencio, E., Romero, F., Gil, A., Lactobacillus paracasei CNCM I-4034 and its culture supernatant modulate Salmonella-induced inflammation in a novel transwell co-culture of human intestinal-like dendritic and Caco-2 cells. BMC Microbiol., 15, 2015, 79.
6. Bjørgo, E., Knappskog, P.M., Martinez, A., Stevens, R.C., Flatmark, T., Partial characterization and three-dimensional-structural localization of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria. Eur. J. Biochem. 257 (1998), 1–10.
7. Cotugno, G., Nicolo, R., Cappelletti, S., Goffredo, B., Dionisi Vici, C., Di Ciommo, V., Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr. 100 (2011), 1144–1149.
8. Ding, Z., Georgiev, P., Thöny, B., Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther. 13 (2006), 587–593.
9. Dobrowolski, S.F., Pey, A.L., Koch, R., Levy, H., Ellingson, C.C., Naylor, E.W., Martinez, A., Biochemical characterization of mutant phenylalanine hydroxylase enzymes and correlation with clinical presentation in hyperphenylalaninaemic patients. J. Inherit. Metab. Dis. 32 (2009), 10–21.
10. Duerr, D.M., White, S.J., Schluesener, H.J., Identification of peptide sequences that induce the transport of phage across the gastrointestinal mucosal barrier. J. Virol. Methods 116 (2004), 177–180.
11. Eavri, R., Lorberboum-Galski, H., A novel approach for enzyme replacement therapy - the use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria. J. Biol. Chem. 282 (2007), 23402–23409.
12. Fan, T., Chen, C., Guo, H., Xu, J., Zhang, J., Zhu, X., Yang, Y., Zhou, Z., Li, L., Huang, Y., Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs. Eur. J. Pharm. Biopharm. 88 (2014), 518–528.
13. Gámez, A., Wang, L., Straub, M., Patch, M.G., Stevens, R.C., Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase. Mol. Ther. 9 (2004), 124–129.
14. Hanley, W.B., Adult phenylketonuria. Am. J. Med. 117 (2004), 590–595.
15. Harding, C.O., Gibson, K., Therapeutic liver repopulation for phenylketonuria. J. Inherit. Metab. Dis. 33 (2010), 681–687.
16. Hashimoto, K., Shimizu, M., Epithelial properties of human intestinal Caco-2 cells cultured in a serum-free medium. Cytotechnology 13 (1993), 175–184.
17. Heintz, C., Troxler, H., Martinez, A., Thony, B., Blau, N., Quantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. Mol. Genet. Metab. 105 (2012), 559–565.
18. Howland, J.L., Ausubel, F., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., Struhl, K., (eds.) Short protocols in molecular biology, third edition, 1996, John Wiley & Sons, New York, 836 (1995. $74.95. ISBN 0-471-13781-2. Biochemical Education 24, 68-68).
19. Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
20. Jurecki, E., BioMarin's Kuvan is first FDA-approved drug for PKU. PKU News 20 (2008), 1–3.
21. Kang, S.K., Woo, J.H., Kim, M.K., Woo, S.S., Choi, J.H., Lee, H.G., Lee, N.K., Choi, Y.J., Identification of a peptide sequence that improves transport of macromolecules across the intestinal mucosal barrier targeting goblet cells. J. Biotechnol. 135 (2008), 210–216.
22. Kang, T.S., Wang, L., Sarkissian, C.N., Gamez, A., Scriver, C.R., Stevens, R.C., Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria. Mol. Genet. Metab. 99 (2010), 4–9.
23. Karlskas, I.L., Maudal, K., Axelsson, L., Rud, I., Eijsink, V.G.H., Mathiesen, G., Heterologous Protein Secretion in Lactobacilli with Modified pSIP Vectors. PLoS One, 2014, 9.
24. Kim, W., Erlandsen, H., Surendran, S., Stevens, R.C., Gamez, A., Michols-Matalon, K., Tyring, S.K., Matalon, R., Trends in enzyme therapy for phenylketonuria. Mol. Ther. 10 (2004), 220–224.
25. Kwon, K.C., Daniell, H., Oral delivery of protein drugs bioencapsulated in plant cells. Mol. Ther. 24 (2016), 1342–1350.
26. Li, H.-S., Piao, D.-C., Jiang, T., Bok, J.-D., Cho, C.-S., Lee, Y.-S., Kang, S.-K., Choi, Y.-J., Recombinant interleukin 6 with M cell-targeting moiety produced in Lactococcus lactis IL1403 as a potent mucosal adjuvant for peroral immunization. Vaccine 33 (2015), 1959–1967.
27. Li, X., Wang, C., Liang, R., Sun, F., Shi, Y., Wang, A., Liu, W., Sun, K., Li, Y., The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles. Pharm. Res. 32 (2015), 1017–1027.
28. Longo, N., Harding, C.O., Burton, B.K., Grange, D.K., Vockley, J., Wasserstein, M., Rice, G.M., Musson, D.G., Gu, Z., Sile, S., Phase 1 trial of subcutaneous rAvPAL-PEG in subjects with phenylketonuria. Lancet, 384, 2014, 37.
29. Malaver, L.F., Alméciga-Díaz, C.J., Morales, I.S., Echeverri, O.Y., Guevara, J., Zuluaga, E., Córdoba-Ruiz, H.A., Barrera, L.A., Plasma amino acid quantification using high performance liquid chromatography. Acta Bioquim. Clin. Latinoam. 43 (2009), 647–660.
30. Mathiesen, G., Sveen, A., Piard, J.C., Axelsson, L., Eijsink, V.G.H., Heterologous protein secretion by Lactobacillus plantarum using homologous signal peptides. J. Appl. Microbiol. 105 (2008), 215–226.
31. Ng, D.T., Sarkar, C.A., Engineering signal peptides for enhanced protein secretion from Lactococcus lactis. Appl. Environ. Microbiol. 79 (2013), 347–356.
32. Oh, Y., Varmanen, P., Han, X.Y., Bennett, G., Xu, Z., Lu, T., Palva, A., Lactobacillus plantarum for oral peptide delivery. Oral Microbiol. Immunol. 22 (2007), 140–144.
33. Ohlsson, A., Bruhn, H., Nordenström, A., Zetterström, R.H., Wedell, A., von Döbeln, U., The Spectrum of PAH Mutations and Increase of Milder Forms of Phenylketonuria in Sweden During 1965–2014. 2016.
34. O'Sullivan, D.J., Klaenhammer, T.R., Rapid mini-prep isolation of high-quality plasmid DNA from Lactococcus and Lactobacillus spp. Appl. Environ. Microbiol. 59 (1993), 2730–2733.
35. Pan, Y., Shen, N., Jung-Klawitter, S., Betzen, C., Hoffmann, G.F., Hoheisel, J.D., Blau, N., CRISPR RNA-guided FokI nucleases repair a PAH variant in a phenylketonuria model. Sci Rep, 6, 2016, 35794.
36. Pusch, O., Boden, D., Hannify, S., Lee, F., Tucker, L.D., Boyd, M.R., Wells, J.M., Ramratnam, B., Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin. JAIDS. J. Acquir. Immune Defic. Syndr. 40 (2005), 512–520.
37. Qiu, Y., Yu, Q., Shi, K., Zhang, M., Zhou, X., Yang, Y., Liu, Y., Tang, J., Wang, X., He, Q., Cell-penetrating peptides induce apoptosis and necrosis through specific mechanism and cause impairment of Na +-K +-ATPase and mitochondria. Amino Acids 49 (2017), 75–88.
38. Rossi, L., Pierige, F., Carducci, C., Gabucci, C., Pascucci, T., Canonico, B., Bell, S.M., Fitzpatrick, P.A., Leuzzi, V., Magnani, M., Erythrocyte-mediated delivery of phenylalanine ammonia lyase for the treatment of phenylketonuria in BTBR-Pah(enu2) mice. J. Control. Release 194 (2014), 37–44.
39. Sambuy, Y., Angelis, I., Ranaldi, G., Scarino, M.L., Stammati, A., Zucco, F., The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 21 (2005), 1–26.
40. Sánchez-Navarro, M., Garcia, J., Giralt, E., Teixidó, M., Using peptides to increase transport across the intestinal barrier. Adv. Drug Deliv. Rev. 106 (2016), 355–366.
41. Sarkissian, C.N., Gámez, A., Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?. Mol. Genet. Metab. 86 (2005), 22–26 (Suppl.).
42. Sarkissian, C.N., Gámez, A., Wang, L., Charbonneau, M., Fitzpatrick, P., Lemontt, J.F., Zhao, B., Vellard, M., Bell, S.M., Henschell, C., Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. 105 (2008), 20894–20899.
43. Sarkissian, C.N., Kang, T.S., Gamez, A., Scriver, C.R., Stevens, R.C., Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of phenylketonuria. Mol. Genet. Metab. 104 (2011), 249–254.
44. Sasikumar, P., Gomathi, S., Anbazhagan, K., Selvam, G.S., Secretion of biologically active heterologous oxalate decarboxylase (OxdC) in Lactobacillus plantarum WCFS1 using homologous signal peptides. Biomed. Res. Int., 2013.
45. Shao, J., Kaushal, G., Normal flora: living vehicles for non-invasive protein drug delivery. Int. J. Pharm. 286 (2004), 117–124.
46. Shi, Z., Sellers, J., Moult, J., Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase. Proteins 80 (2012), 61–70.
47. Sirtori, L.R., Dutra-Filho, C.S., Fitarelli, D., Sitta, A., Haeser, A., Barschak, A.G., Wajner, M., Coelho, D.M., Llesuy, S., Belló-Klein, A., Giugliani, R., Deon, M., Vargas, C.R., Oxidative stress in patients with phenylketonuria. Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1740 (2005), 68–73.
48. Skory, C.D., Côté, G.L., Secreted expression of Leuconostoc mesenteroides glucansucrase in Lactococcus lactis for the production of insoluble glucans. Appl. Microbiol. Biotechnol. 99 (2015), 10001–10010.
49. Sørvig, E., Grönqvist, S., Naterstad, K., Mathiesen, G., Eijsink, V.G., Axelsson, L., Construction of vectors for inducible gene expression in Lactobacillus sakei and L. plantarum. FEMS Microbiol. Lett. 229 (2003), 119–126.
50. Sulzbacher, A., Jarosch, A., Schuler, R., Acerbi, D., Ventura, P., Puccini, P., Woodcock, B.G., Validation of a Caco-2 cell monolayer culture for drug transport studies. Int. J. Clin. Pharmacol. Ther. 36 (1998), 86–89.
51. van Asseldonk, M., Rutten, G., Oteman, M., Siezen, R.J., de Vos, W.M., Simons, G., Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 95 (1990), 155–160.
52. van Spronsen, F.J., Enns, G.M., Future treatment strategies in phenylketonuria. Mol. Genet. Metab. 99 (2010), S90–S95.
53. van Vliet, D., Anjema, K., Jahja, R., de Groot, M.J., Liemburg, G.B., Heiner-Fokkema, M.R., van der Zee, E.A., Derks, T.G., Kema, I.P., van Spronsen, F.J., BH4 treatment in BH4-responsive PKU patients: preliminary data on blood prolactin concentrations suggest increased cerebral dopamine concentrations. Mol. Genet. Metab. 114 (2015), 29–33.
54. Wadia, J.S., Stan, R.V., Dowdy, S.F., Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004), 310–315.
55. Wells, J.M., Mercenier, A., Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol. 6 (2008), 349–362.
56. Zhang, J., Zhu, X., Jin, Y., Shan, W., Huang, Y., Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles. Mol. Pharm. 11 (2014), 1520–1532.